District Court Grants Summary Judgment and Invalidates Patent in REGENXBIO v. Sarepta Litigation
LexBlog IP
JANUARY 8, 2024
On January 5, 2024, in litigation between REGENXBIO and Sarepta Therapeutics, Judge Richard Andrews of the U.S. 10,526,617 (the ’617 Patent; licensed to REGENXBIO) is invalid as being directed to ineligible subject matter. A trial was scheduled to begin on January 29, 2024. last year is ongoing. § 101.
Let's personalize your content